SCHEMBL9155161

SCHEMBL9155161

CCOP(=O)(O)Oc1ccc(CCN)cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
NFKB1 P19838 1/20 0.56
LMNA P02545 3/20 0.55
APEX1 P27695 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TAAR1 Q96RJ0 4/20 0.47
MAPK1 P28482 3/20 0.47
BACE1 P56817 1/20 0.47
GLA P06280 1/20 0.46
KDM4E B2RXH2 3/20 0.45
ADRA2A P08913 2/20 0.45
MAPT P10636 2/20 0.45
DRD2 P14416 2/20 0.45
DRD1 P21728 2/20 0.45
DRD4 P21917 2/20 0.45
DRD5 P21918 2/20 0.45
SLC6A2 P23975 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9151954 0.84 MAPT (0.50) TSHRCYP1A2CYP3A4NFKB1LMNA
SCHEMBL10606400 0.84 TSHR (0.40) TSHRCYP1A2CYP3A4NFKB1LMNA
SCHEMBL9156756 0.83 TSHR (0.61) TSHRCYP1A2CYP3A4NFKB1LMNA
Hydrochloric Acid SCHEMBL9152256 0.81 LMNA (0.62) TSHRCYP1A2CYP3A4NFKB1LMNA
SCHEMBL9155889 0.78 TSHR (0.44) TSHRCYP1A2CYP3A4NFKB1LMNA
SCHEMBL10600900 0.75 ADRB2 (0.60) TSHRCYP1A2CYP3A4NFKB1LMNA
Hydrochloric Acid SCHEMBL11548357 0.75 LMNA (0.71) TSHRCYP1A2CYP3A4NFKB1LMNA
SCHEMBL9150874 0.74 MAPT (0.41) LMNAMEN1KMT2AMAPTALDH1A1
Ammonia Solution, Strong SCHEMBL9155909 0.74 SMN1; SMN2 (0.45) LMNAMEN1KMT2AMAPTALDH1A1
SCHEMBL29351790 0.73 TSHR (1.00) TSHRCYP1A2CYP3A4NFKB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP claimed
US-4673671-A CONVERSION TO MONO O-PHOSPHATE ESTER SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1987-06-16 US claimed
EP-0430336-B1 Process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives ZAMBON SPA (IT) 1995-02-15 EP disclosed
US-5138084-A PROCESS FOR THE PREPARATION OF 4-O-PHOSPHATES OF DOPAMINE AND DOPAMINE DERIVATIVES SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1992-08-11 US disclosed
EP-0430336-A2 Process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives ZAMBON GROUP S.p.A. (IT) 1991-06-05 EP disclosed
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP disclosed
US-4673671-A CONVERSION TO MONO O-PHOSPHATE ESTER SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1987-06-16 US disclosed